2025年12月易方达旗下15只基金跌超9% 最深下跌12%

Core Insights - In December 2025, a total of 298 out of 1,054 comparable ordinary equity funds experienced a decline in net value, while 1,897 out of 8,755 comparable mixed funds and 453 out of 692 comparable QDII funds also saw a decrease in net value [1] Group 1: Fund Performance - Among the funds managed by E Fund, 15 funds fell by over 8%, with specific declines including E Fund Hang Seng Stock Connect Innovative Drug ETF at -12.05%, E Fund Medical Biotechnology Stock C at -12.03%, and E Fund Medical Biotechnology Stock A at -12.00% [2] - The performance of E Fund's various funds shows significant declines, with the worst performers being E Fund Hang Seng Stock Connect Innovative Drug ETF and its linked versions, as well as several medical and healthcare-focused funds [2][3] Group 2: Fund Management - The funds experiencing the largest declines are managed by different fund managers, including Cheng Xi for several E Fund Hang Seng and medical funds, and Yang Zhenshao for various healthcare and QDII funds [3]